Management of urinary retention due to benign prostatic hyperplasia using luteinizing hormone-releasing hormone agonist. uri icon

Overview

abstract

  • A common affliction of older men is bladder outlet obstruction secondary to benign prostatic hyperplasia for which the standard treatment is surgical prostatectomy. We report on six men with urinary retention from benign prostatic hyperplasia who were not medically able to undergo surgical prostatectomy but were successfully treated with the luteinizing hormone-releasing hormone (LH-RH) agonist, leuprolide acetate. This therapy is exemplified by the case of a sixty-six-year-old man with hemophilia B and urinary retention. The patient was treated with daily subcutaneous injections of 1 mg of leuprolide acetate, and prostatic size decreased from 132 g to 42 g, with initiation of spontaneous micturition while on treatment. For patients with symptomatic benign prostatic hyperplasia who are not candidates for surgery, treatment with an LH-RH agonist, such as leuprolide acetate, should be considered as a possible alternative.

publication date

  • August 1, 1989

Research

keywords

  • Gonadotropin-Releasing Hormone
  • Prostatic Hyperplasia
  • Urination Disorders

Identity

Scopus Document Identifier

  • 0024313763

Digital Object Identifier (DOI)

  • 10.1016/0090-4295(89)90165-9

PubMed ID

  • 2474882

Additional Document Info

volume

  • 34

issue

  • 2